SG11201506755XA - Use of (rs)-s-cyclopropyl-s-(4-{[4-{[(1r,2r)-2-hydroxy-1-methylpropyl]- oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide for treatment of specific tumours - Google Patents

Use of (rs)-s-cyclopropyl-s-(4-{[4-{[(1r,2r)-2-hydroxy-1-methylpropyl]- oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide for treatment of specific tumours

Info

Publication number
SG11201506755XA
SG11201506755XA SG11201506755XA SG11201506755XA SG11201506755XA SG 11201506755X A SG11201506755X A SG 11201506755XA SG 11201506755X A SG11201506755X A SG 11201506755XA SG 11201506755X A SG11201506755X A SG 11201506755XA SG 11201506755X A SG11201506755X A SG 11201506755XA
Authority
SG
Singapore
Prior art keywords
sulfoximide
methylpropyl
pyrimidin
cyclopropyl
oxy
Prior art date
Application number
SG11201506755XA
Inventor
Gerhard Siemeister
Vincent Ribrag
Valérie Camara-Clayette
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50189709&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201506755X(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of SG11201506755XA publication Critical patent/SG11201506755XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SG11201506755XA 2013-03-07 2014-02-28 Use of (rs)-s-cyclopropyl-s-(4-{[4-{[(1r,2r)-2-hydroxy-1-methylpropyl]- oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide for treatment of specific tumours SG11201506755XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102013203913 2013-03-07
PCT/EP2014/053975 WO2014135460A1 (en) 2013-03-07 2014-02-28 Use of (rs)-s-cyclopropyl-s-(4-{[4-{[(1r,2r)-2-hydroxy-1-methylpropyl]- oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide for treatment of specific tumours

Publications (1)

Publication Number Publication Date
SG11201506755XA true SG11201506755XA (en) 2015-09-29

Family

ID=50189709

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201506755XA SG11201506755XA (en) 2013-03-07 2014-02-28 Use of (rs)-s-cyclopropyl-s-(4-{[4-{[(1r,2r)-2-hydroxy-1-methylpropyl]- oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide for treatment of specific tumours

Country Status (19)

Country Link
US (1) US20160045496A1 (en)
EP (1) EP2964259A1 (en)
JP (1) JP2016513619A (en)
KR (1) KR20150128783A (en)
CN (1) CN105007945A (en)
AP (1) AP2015008753A0 (en)
AU (1) AU2014224737A1 (en)
BR (1) BR112015021550A2 (en)
CA (1) CA2904149A1 (en)
CL (1) CL2015002491A1 (en)
EA (1) EA201591625A1 (en)
HK (1) HK1211229A1 (en)
IL (1) IL240977A0 (en)
MX (1) MX2015011800A (en)
PH (1) PH12015501969A1 (en)
SG (1) SG11201506755XA (en)
TN (1) TN2015000387A1 (en)
TW (1) TW201501712A (en)
WO (1) WO2014135460A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010014426A1 (en) * 2010-04-01 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Use of new pan-CDK inhibitors for the treatment of tumors
US9241941B2 (en) * 2012-09-20 2016-01-26 Memorial Sloan-Kettering Cancer Center Methods for treatment of lymphomas with mutations in cell cycle genes

Also Published As

Publication number Publication date
IL240977A0 (en) 2015-11-30
HK1211229A1 (en) 2016-05-20
AU2014224737A1 (en) 2015-09-24
EA201591625A1 (en) 2016-03-31
KR20150128783A (en) 2015-11-18
CA2904149A1 (en) 2014-09-12
JP2016513619A (en) 2016-05-16
US20160045496A1 (en) 2016-02-18
BR112015021550A2 (en) 2017-07-18
TN2015000387A1 (en) 2017-01-03
AP2015008753A0 (en) 2015-09-30
PH12015501969A1 (en) 2016-01-18
EP2964259A1 (en) 2016-01-13
WO2014135460A1 (en) 2014-09-12
MX2015011800A (en) 2016-01-08
TW201501712A (en) 2015-01-16
CN105007945A (en) 2015-10-28
CL2015002491A1 (en) 2016-01-15

Similar Documents

Publication Publication Date Title
HK1212207A1 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
DK2976360T3 (en) THERAPY INVOLVED ANTIBODIES AGAINST CLAUDIN 18.2 FOR CANCER TREATMENT
SG2014008304A (en) C10rf32 antibodies, and uses thereof for treatment of cancer
SG10201704992SA (en) Lsr antibodies, and uses thereof for treatment of cancer
ZA201702720B (en) 1-alkyl-6-oxo-1,6-dihydropyridin-3-yl compounds and use as sgrm modulators
EP2807551A4 (en) Roaming of note-taking application features
EP3007756A4 (en) Catheter-assisted tumor treatment
SG11201510594YA (en) Mixtures of compounds, their preparation, and uses
GB201407296D0 (en) Modification of extracorporeal protopheresis technology with porphyrin precursors
GEP20186871B (en) Benzamide and nicotinamide compounds and methods of using same
HK1249898A1 (en) C,o-spiro aryl glycoside compounds, preparation therefor and use thereof
GB201403716D0 (en) Catalytic treatment
HK1219234A1 (en) Novel breathing control modulating compounds, and methods of using same
ZA201406986B (en) Use of (rs)-s-cyclopropyl-s-(4-{[4-{[1r, 2r)-2-hydroxy-1-methylpropyl]oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide for treating specific tumours
ZA201706543B (en) Catalyst precursor, method of preparation and use thereof
DK3725810T3 (en) COMBINATION THERAPY INVOLVING ANTIBODIES TO CLAUDIN 18.2 FOR THE TREATMENT OF CANCER
IL240977A0 (en) Use of (rs)-s-cyclopropyl-s-(4-{[4-{[(1r,2r)-2-hydroxy-1-methylpropyl]- oxy}-5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide for treatment of specific tumours
DK3081560T3 (en) Taxane compounds, process for their preparation and use
GB201303737D0 (en) Catalytic treatment
GB201517329D0 (en) Diabetes gene therapy
GB201808124D0 (en) Wireless oximeter for continuous use
HK1224215A1 (en) Use of high dose pridopidine for treating huntingtons disease
IL232340A0 (en) Lsr antibodies, and uses thereof for treatment of cancer